Bladder preservation: Translating discovery for clinical impact in urothelial cancer

David T. Miyamoto, Philip H. Abbosh, Catharine M.L. West, Kent W. Mouw

Research output: Contribution to journalReview articlepeer-review

3 Scopus citations

Abstract

Muscle-invasive bladder cancer can be treated with either radical cystectomy or bladder preservation approaches, and there is a need for reliable biomarkers to guide the optimal choice of therapy. The recent elucidation of the genomic landscape and biological drivers of bladder cancer has enabled the identification of tumor molecular features that may be helpful in driving clinical decision-making. Here, we summarize recent efforts to develop molecular biomarkers that could be leveraged to guide therapeutic decisions, post-treatment monitoring, and the optimal use of bladder preservation approaches for the effective treatment of muscle-invasive bladder cancer.

Original languageEnglish
Pages (from-to)201-208
Number of pages8
JournalUrologic Oncology: Seminars and Original Investigations
Volume39
Issue number4
DOIs
StatePublished - Apr 2021

Keywords

  • Carcinoma, Transitional Cell/surgery
  • Humans
  • Organ Sparing Treatments
  • Urinary Bladder Neoplasms/surgery

Fingerprint

Dive into the research topics of 'Bladder preservation: Translating discovery for clinical impact in urothelial cancer'. Together they form a unique fingerprint.

Cite this